← Back to Search

Flavonoid

Fisetin for Improved Vascular Function in Aging

Phase 1 & 2

Recruiting

Led By Matthew J Rossman, PhD

Research Sponsored by University of Colorado, Boulder

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 65 years or older

Women must be postmenopausal

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 month

Awards & highlights

Study Summary

This trial tests if a flavonoid compound, fisetin, can improve vascular function in older adults by reducing mitochondrial oxidative stress, cellular senescence, and SASP factors. It will also evaluate safety, tolerability, and adherence.

Who is the study for?

This trial is for people aged 65 or older, specifically postmenopausal women and men with a BMI under 40. Participants should not have had significant weight changes recently, must be free of serious chronic diseases like unstable heart conditions, and agree to not donate blood during the study.Check my eligibility

What is being tested?

The trial is testing fisetin, a flavonoid compound thought to improve blood vessel function and reduce stiffness in arteries among older adults. It will compare fisetin's effects against a placebo while exploring how it might work by affecting oxidative stress and other aging-related factors.See study design

What are the potential side effects?

While specific side effects are not listed here, the trial will monitor how well participants can tolerate fisetin and any adverse reactions they experience. This includes checking for any discomfort or health issues that arise during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 65 years old or older.

Select...

I have gone through menopause.

Select...

My weight has been stable for the last 2 months and I can keep it stable during the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline in endothelial function at 1 month

Secondary outcome measures

Change from baseline in aortic stiffness at 1 month

Other outcome measures

Change from baseline in blood cell markers of cellular senescence at 1 month

Change from baseline in endothelial cell markers of cellular senescence at 1 month

Change from baseline in plasma markers of the senescence-associated secretory phenotype

+1 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: FisetinActive Control1 Intervention

Fisetin will be administered in an intermittent manner with two, three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks.

Group II: PlaceboPlacebo Group1 Intervention

Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with two, three-day dosing periods separated by two weeks.

0 / 3Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

American Heart AssociationOTHER

326 Previous Clinical Trials

4,933,556 Total Patients Enrolled

University of Colorado, BoulderLead Sponsor

119 Previous Clinical Trials

29,124 Total Patients Enrolled

Matthew J Rossman, PhDPrincipal InvestigatorUniversity of Colorado, Boulder

3 Previous Clinical Trials

196 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts still underway for this research project?

"Affirmative. Clinicaltrials.gov has documented that this medical experiment, which was first published on the 25th of September 2023, is actively enrolling patients. This research requires 70 participants from a single site to be recruited."

Answered by AI

What is the scope of individuals receiving treatment as part of this experiment?

"Affirmative, the information hosted on clinicaltrials.gov reveals that this research is actively in need of participants. Originally posted on September 25th 2023 and updated November 10th 2023, the trial has a recruitment goal of 70 patients from 1 medical site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Fisetin to Improve Vascular Function in Older Adults

Matthew Rossman 2023. "Fisetin to Improve Vascular Function in Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06133634.

All > Denver > Colorado Springs